Rakovina Historical Balance Sheet
| RKV Stock | CAD 0.11 0.02 15.38% |
Trend analysis of Rakovina Therapeutics balance sheet accounts such as Total Current Liabilities of 103.3 K, Net Receivables of 30 K, Total Current Assets of 954.6 K or Total Assets of 5.3 M provides information on Rakovina Therapeutics' total assets, liabilities, and equity, which is the actual value of Rakovina Therapeutics to its prevalent stockholders. By breaking down trends over time using Rakovina Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Rakovina |
About Rakovina Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Rakovina Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Rakovina Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Rakovina Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Rakovina currently owns. An asset can also be divided into two categories, current and non-current.
Rakovina Therapeutics Balance Sheet Chart
Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on Rakovina Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Rakovina Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Rakovina Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Rakovina Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rakovina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Rakovina Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Common Stock is likely to climb to about 16.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 103.3 K in 2025.
| 2021 | 2024 | 2025 (projected) | Other Current Liabilities | 74.3K | 85.5K | 89.7K | Common Stock | 13.6M | 15.6M | 16.4M |
Rakovina Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Rakovina Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rakovina Therapeutics balance sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Retained Earnings | (13.0) | (5.5M) | (8.3M) | (10.9M) | (9.8M) | (9.3M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.